Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

Sun Pharma Group Stocks

1 Yr CAGR 7.08%

3 Yr CAGR 11.83%

Total Companies 3

List of Sun Pharma Stocks as on 13-Oct-2026

Filter

	Company Name	DeciZen	CMP	Price Change	Market Cap (Cr)	52 Week High	52 Week Low	ROE	P/E Ratio	P / BV	EV/ EBITDA
1	Zenotech Labs.	4 Q V+ PT	42.25	-1.90%	263 Small Cap	54.14 31 Oct, 25	33.55 30 Mar, 26	-0.92	-	2.78	23.84	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Sun Pharma. Inds.	4 Q V PT	1,759	0.13%	4,21,539 Large Cap	2,048 31 Jul, 26	1,584 29 Jan, 26	14.80	34.85	4.87	20.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Sun Pharma Adv. Res	4 Q V+ PT	185	-0.19%	6,015 Small Cap	289 08 Jul, 26	108 23 Mar, 26	279.64	3.80	4.56	4.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Top Business Houses

Tata

26 Companies

Market Cap: ₹ 24,42,801 Cr.

1 Yr CAGR -10.14%

3 Yr CAGR 1.12%

Mukesh Ambani

8 Companies

Market Cap: ₹ 17,39,552 Cr.

1 Yr CAGR -22.11%

3 Yr CAGR -5.68%

Adani

7 Companies

Market Cap: ₹ 15,73,480 Cr.

1 Yr CAGR 16.13%

3 Yr CAGR 9.26%

Bajaj

12 Companies

Market Cap: ₹ 13,65,554 Cr.

1 Yr CAGR -13.02%

3 Yr CAGR 15.20%

HDFC

4 Companies

Market Cap: ₹ 13,56,709 Cr.

1 Yr CAGR -13.79%

3 Yr CAGR 2.61%

Bharti

3 Companies

Market Cap: ₹ 13,03,862 Cr.

1 Yr CAGR -9.18%

3 Yr CAGR 23.31%

ICICI

4 Companies

Market Cap: ₹ 12,72,970 Cr.

1 Yr CAGR 0.05%

3 Yr CAGR 6.68%

PSU - SBI

4 Companies

Market Cap: ₹ 12,08,309 Cr.

1 Yr CAGR -12.05%

3 Yr CAGR 3.88%

News about Sun Pharma Stocks in India

Oct, 2026

Sun Pharma planning to raise Rs 15,000 crore via NCDs

A meeting of the Board of Directors of the Company is scheduled to be held on October 12, 2026, inter alia, to consider and approve the same

Sep, 2026

Sun Pharma inks pact with LIB Therapeutics for ‘lerodalcibep’

Sun Pharma has been granted rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China

Sep, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed copy of the press release titled ‘LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a PCSK9 Inhibitor, Ex-US and China; Lyrokaul (lerodalcibep) Approved in the EU’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Sep, 2026

Sun Pharmaceutical incorporates subsidiary in GIFT City

The new entity has been incorporated to operate as the Global Treasury Centre for the Sun Pharma Group

Sep, 2026

Sun Pharmaceutical Industries informs about incorporation of subsidiary company

Sun Pharmaceutical Industries has informed that ‘Sun Pharma Global Treasury Centre IFSC’ has been incorporated on 08 September 2026 as an indirect wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India. The disclosures required under Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Sep, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

You have 95 views remaining as a Guest User. Login | Register Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Current Complaints

^ Average Resolution time is the sum total of time taken to resolve each complaint in days, in the current month divided by total number of complaints resolved in the current month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Sun Pharma Group Stocks

Top Business Houses

Tata

Mukesh Ambani

Adani

Bajaj

HDFC

Bharti

ICICI

PSU - SBI

News about Sun Pharma Stocks in India

Sun Pharma planning to raise Rs 15,000 crore via NCDs

Sun Pharma inks pact with LIB Therapeutics for ‘lerodalcibep’

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical incorporates subsidiary in GIFT City

Sun Pharmaceutical Industries informs about incorporation of subsidiary company

Sun Pharmaceutical Industries informs about press release

Track Now:

Trending Blogs